We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+22.97%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.81B
AUM Growth
-$1.23B
Cap. Flow
-$2B
Cap. Flow %
-34.5%
Top 10 Hldgs %
69.35%
Holding
53
New
7
Increased
14
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$374M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$100M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$96.8M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$81.7M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$60.1M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$2.23B
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$257M
3
KPTI icon
Karyopharm Therapeutics
KPTI
+$87.6M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$80.8M
5
QURE icon
uniQure
QURE
+$64.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYOK
51
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-1,885,000
Closed -$257M
IMMU
52
DELISTED
Immunomedics Inc
IMMU
– –
-26,250,000
Closed -$2.23B
ZGNX
53
DELISTED
Zogenix, Inc.
ZGNX
– –
-875,000
Closed -$15.7M
1 2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Avoro Capital Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, Avoro Capital Advisors held 53 positions worth $5.81B, down 18% from $7.04B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Avoro Capital Advisors withdrew a net $2B in Q4 2020, closing 9 positions and reducing 8 holdings. Its most notable exit was Immunomedics Inc, an estimated $2.23B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 67% a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in United Therapeutics worth $433M.

  • Avoro Capital Advisors's largest Q4 2020 buy was United Therapeutics: 2,850,000 shares worth $433M.
  • Avoro Capital Advisors added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020, an estimated $100M increase.
  • Avoro Capital Advisors's biggest Q4 2020 reduction was Iovance Biotherapeutics, cutting an estimated $80.8M.
  • Avoro Capital Advisors fully exited Immunomedics Inc in Q4 2020, selling an estimated $2.23B.
  • Avoro Capital Advisors's ten largest holdings make up 69% of its $5.81B portfolio in Q4 2020.
  • Avoro Capital Advisors opened 7 new positions and closed 9 in Q4 2020.
  • Avoro Capital Advisors's portfolio value fell 18% quarter-over-quarter to $5.81B.

Based on Avoro Capital Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.